Skip to main content Accessibility help
×
Home
Hostname: page-component-ffbbcc459-7c245 Total loading time: 0.37 Render date: 2022-03-06T11:15:14.618Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Glioblastoma Treatment in the Elderly in the Temozolomide Therapy Era

Published online by Cambridge University Press:  23 September 2014

Linda Coate
Affiliation:
Pencer Brain Tumour Centre, Princess Margaret Cancer Centre, Toronto, Ontario, Canada Mid-Western Regional Hospital Limerick, Limerick, Ireland
Mairéad G. McNamara
Affiliation:
Pencer Brain Tumour Centre, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Zarnie Lwin
Affiliation:
Pencer Brain Tumour Centre, Princess Margaret Cancer Centre, Toronto, Ontario, Canada Department of Medical Oncology, Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, Australia
Derek MacFadden
Affiliation:
Pencer Brain Tumour Centre, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Ahmed Al-Zahrani
Affiliation:
Pencer Brain Tumour Centre, Princess Margaret Cancer Centre, Toronto, Ontario, Canada Department of Medical Oncology, King Faisal Cancer Center, Riyadh, Saudi Arabia
Christine Massey
Affiliation:
Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Cynthia Menard
Affiliation:
Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Barbara Ann Millar
Affiliation:
Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Arjun Sahgal
Affiliation:
Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Normand Laperriere
Affiliation:
Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Warren P. Mason*
Affiliation:
Pencer Brain Tumour Centre, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
*
*Pencer Brain Tumour Centre, Princess Margaret Cancer Centre, 610 University Avenue, Suite 18-717, Toronto, Ontario, M5G 2M9, Canada. Email: warren.mason@uhn.ca
Rights & Permissions[Opens in a new window]

Abstract

HTML view is not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Optimal treatment of glioblastoma (GBM) in the elderly remains unclear. The impact of age on treatment planning, toxicity, and efficacy at a Canadian Cancer Centre was retrospectively reviewed.

Methods:

Glioblastoma patients treated consecutively between 2004 and 2008 were reviewed. Utilizing 70 years as the threshold for definition of an elderly patient, treatments and outcome were compared in younger and elderly populations.

Results:

Four hundred and twenty one patients were included in this analysis and median overall survival (OS) for the entire cohort was 9.8 months. 290 patients were aged <70 (median age 57, range 17–69) and 131 were aged ≥70 (median age 76, range 70–93). Patients ≥70 were more likely to receive best supportive care (BSC) and all patients >70 who were treated with radiotherapy received <60 Gy (P<0.001), except one. Patients aged >70 demonstrated inferior survival (one year OS 16% versus 54% for those <70, HR 3.46, P<0.001). In patients treated with BSC only, age had no impact on survival (median survival two months in both groups, HR 0.89, P=0.75). For those treated with higher doses of radiotherapy (>30 Gy to <60 Gy), one year survival was 19% versus 24% in patients aged >70 versus <70 (HR 1.47, P=0.02) respectively.

Conclusions:

In this retrospective single institution series, elderly patients were more likely to be treated with BSC or palliative doses of radiotherapy. Randomized phase III study results are required for guidance in treatment of this population of patients.

Type
Original Article
Copyright
Copyright © The Canadian Journal of Neurological 2014

References

1.Wen, PY, Kesari, S. Malignant gliomas in adults. N Engl J Med. 2008 359(8)492507.CrossRefGoogle ScholarPubMed
2.Fisher, JL, Schwartzbaum, JA, Wrensch, M, Wiemels, JL. Epidemiology of brain tumors. Neurol Clin. 2007 25(4)86790.CrossRefGoogle ScholarPubMed
3.Hess, KR, Broglio, KR, Bondy, ML. Adult glioma incidence trends in the United States, 1977–2000. Cancer. 2004 101(10)22939.CrossRefGoogle ScholarPubMed
4.Sahebjam, S, McNamara, M, Mason, WP. Management of glioblastoma in the elderly. Clin Adv Hematol Oncol. 2012 10(6)37986.Google ScholarPubMed
5.Buckner, JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003 30(6)1014.CrossRefGoogle ScholarPubMed
6.Scott, JG, Bauchet, L, Fraum, TJ. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer. 2012 118(22)5595600.CrossRefGoogle ScholarPubMed
7.Keime-Guibert, F, Chinot, O, Taillandier, L. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007 356(15)152735.CrossRefGoogle ScholarPubMed
8.Walker, MD, Alexander, E Jr, Hunt, WE. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978 49(3)33343.CrossRefGoogle ScholarPubMed
9.Lutterbach, J, Ostertag, C. What is the appropriate radiotherapy protocol for older patients with newly diagnosed glioblastoma?. J Clin Oncol. 2005 23(12)286970.CrossRefGoogle ScholarPubMed
10.Roa, W, Brasher, PM, Bauman, G. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004 22(9)15838.CrossRefGoogle ScholarPubMed
11.Stupp, R, Mason, WP, van den Bent, MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 352(10)98796.CrossRefGoogle ScholarPubMed
12.Stupp, R, Hegi, ME, Mason, WP. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 10(5)45966.CrossRefGoogle Scholar
13.National Institutes of Health webpage. Everolimus, temozolomide, and radiation therapy in treating patients with newly diagnosed glioblastoma multiforme (RTOG 0913). [updated 2013 Oct 3; refd 2013 Nov 1]. Available from: www.ClinicalTrials.gov Identifier: NCT01062399.Google Scholar
14.National Institutes of Health webpage. Radiation therapy with or without temozolomide in treating older patients with newly diagnosed glioblastoma multiforme. [updated 2013 May 22; refd 2013 Nov 1]. Available from: www.ClinicalTrials.gov Identifier: NCT00482677.Google Scholar
15.Malmstrom, A, Gronberg, BH, Marosi, C. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012 13(9)91626.CrossRefGoogle ScholarPubMed
16.Minniti, G, De Sanctis, V, Muni, R. Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol. 2009 91(1)95100.CrossRefGoogle ScholarPubMed
17.Brandes, AA, Vastola, F, Basso, U. A prospective study on glioblastoma in the elderly. Cancer. 2003 97(3)65762.CrossRefGoogle ScholarPubMed
18.Minniti, G, De Sanctis, V, Muni, R. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol. 2008 88(1)97103.CrossRefGoogle ScholarPubMed
19.Minniti, G, Lanzetta, G, Scaringi, C. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2012 83(1)939.CrossRefGoogle ScholarPubMed
20.Wick, W, Platten, M, Meisner, C. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012 13(7)70715.CrossRefGoogle ScholarPubMed
You have Access
4
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Glioblastoma Treatment in the Elderly in the Temozolomide Therapy Era
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Glioblastoma Treatment in the Elderly in the Temozolomide Therapy Era
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Glioblastoma Treatment in the Elderly in the Temozolomide Therapy Era
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *